New Zealand vs Singapore: Prevalence rate of hypertension in women aged 30-79
New Zealand
27.6
in 2019
Singapore
27.1
in 2019
New Zealand rank
164th
Singapore rank
166th
Prevalence rate of hypertension in women aged 30-79 over time
- New Zealand
- Singapore
How they compare
New Zealand currently reports 27.6 against 27.1 in Singapore, a difference of 0.5.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Singapore ahead.
New Zealand ranks 164th and Singapore ranks 166th of 195 countries.
Singapore has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | New Zealand | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 31.27 | 37.14 | 5.87 | Singapore |
| 2000s | 30.15 | 33.4 | 3.25 | Singapore |
| 2010s | 28.63 | 29.2 | 0.57 | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in women aged 30-79, New Zealand or Singapore?
- New Zealand, at 27.6 against 27.1 in Singapore as of 2019.
- What is the difference in prevalence rate of hypertension in women aged 30-79 between New Zealand and Singapore?
- 0.5, with New Zealand ahead.
- How many years of comparable data are there for New Zealand and Singapore?
- 30 years are reported by both, from 1990 to 2019.
- How do New Zealand and Singapore rank globally for prevalence rate of hypertension in women aged 30-79?
- New Zealand ranks 164th and Singapore ranks 166th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in women aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of female population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.